Skip to main content
. 2021 May 24;22(1):43. doi: 10.1186/s10194-021-01258-y

Fig. 2.

Fig. 2

General use (%) of pharmacological classes of preventive treatment according to each country in patients without comorbidities (200/600). All treatment classes use between countries resulted statistically significantly different (p<0.0001). AU: Australia; IT: Italy; DE: Germany; PL: Poland; PT: Portugal; RUS: Russia; ES: Spain; AD: antidepressants; AEDs: anti-epileptic drugs; BB&AHT: beta-blockers and antihypertensive drugs; BTX-A: Onabotulinumtoxin A.